Head to Head Contrast: Cidara Therapeutics (CDTX) vs. Heska (HSKA)

Cidara Therapeutics (NASDAQ: CDTX) and Heska (NASDAQ:HSKA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cidara Therapeutics and Heska, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cidara Therapeutics 0 0 3 0 3.00
Heska 0 1 5 0 2.83

Cidara Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 187.04%. Heska has a consensus price target of $114.90, suggesting a potential upside of 7.27%. Given Cidara Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cidara Therapeutics is more favorable than Heska.

Insider and Institutional Ownership

64.1% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 89.2% of Heska shares are owned by institutional investors. 15.2% of Cidara Therapeutics shares are owned by company insiders. Comparatively, 15.9% of Heska shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cidara Therapeutics and Heska’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cidara Therapeutics N/A -106.22% -79.34%
Heska 5.57% 13.30% 10.01%

Volatility and Risk

Cidara Therapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Heska has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cidara Therapeutics and Heska’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cidara Therapeutics N/A N/A -$55.72 million ($3.18) -1.70
Heska $129.34 million 6.18 $9.95 million $2.07 51.74

Heska has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Summary

Heska beats Cidara Therapeutics on 10 of the 13 factors compared between the two stocks.

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply